Watch the interview with Targintas vd Per Norlen below.
An exciting year awaits oncology company Targinta, with the upcoming spin-off from parent company Xintela in focus. CEO Per Norlén visited BioStock's studio to talk more about this and the company's targeted antibodies for the treatment of aggressive cancers such as triple-negative breast cancer.